Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system drugs including antidepressants, antipsychotics, and antiepileptic products... Show more
HLUBF saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on August 13, 2025. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 20 instances where the indicator turned negative. In of the 20 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 14 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Momentum Indicator moved below the 0 level on August 11, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on HLUBF as a result. In of 22 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.199) is normal, around the industry mean (16.657). P/E Ratio (8.309) is within average values for comparable stocks, (72.172). Projected Growth (PEG Ratio) (5.973) is also within normal values, averaging (4.696). Dividend Yield (0.030) settles around the average of (0.031) among similar stocks. P/S Ratio (1.233) is also within normal values, averaging (40.190).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. HLUBF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HLUBF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
Industry PharmaceuticalsGeneric
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
RYPMX | 188.31 | N/A | N/A |
Rydex Precious Metals Inv | |||
IVIPX | 30.61 | N/A | N/A |
VY® Invesco Equity and Income S2 | |||
KLCSX | 20.96 | N/A | N/A |
Federated Hermes Kaufmann Large Cap R6 | |||
TRWIX | 24.93 | N/A | N/A |
Transamerica International Equity I2 | |||
CGFCX | 72.63 | -0.05 | -0.07% |
American Funds Growth Fund of Amer 529C |
A.I.dvisor tells us that HLUBF and HLBBF have been poorly correlated (+18% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that HLUBF and HLBBF's prices will move in lockstep.
Ticker / NAME | Correlation To HLUBF | 1D Price Change % | ||
---|---|---|---|---|
HLUBF | 100% | N/A | ||
HLBBF - HLUBF | 18% Poorly correlated | N/A | ||
HLNCF - HLUBF | 7% Poorly correlated | +2.77% | ||
ESAIY - HLUBF | 5% Poorly correlated | +2.73% | ||
AKAN - HLUBF | 2% Poorly correlated | -0.73% | ||
HLN - HLUBF | 1% Poorly correlated | +0.10% | ||
More |
Ticker / NAME | Correlation To HLUBF | 1D Price Change % |
---|---|---|
HLUBF | 100% | N/A |
Pharmaceuticals category (393 stocks) | -0% Poorly correlated | -0.36% |
Pharmaceuticals: Generic category (227 stocks) | -0% Poorly correlated | -0.30% |